To further assess CDK11 for myeloma-selective vulnerability, the study evaluated the expression of CDK11 in human multiple myeloma, and showed that CDK11 is significantly upregulated in expression in primary multiple myeloma tissues, as compared with normal human primary tissues. This evidence concerns the gene CDK19 and plasma cell myeloma.